• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices

Corium

Corium touts study results for once-daily ADHD capsule

October 14, 2021 By Sean Whooley

Corium (NSDQ:CORI) today announced clinical data demonstrating the strong performance of its once-daily ADHD capsule. Boston-based Corium’s Azstarys oral capsule for treating ADHD symptoms (serdexmethylphenidate [SDX] and dexmethylphenidate [d-MPH]) received FDA approval in March as the first and only product containing a d-MPH oral prodrug for treating ADHD (attention deficit hyperactivity disorder) symptoms in patients aged six […]

Filed Under: Clinical Trials, Featured, Neurological, Pediatrics, Pharmaceutical Tagged With: Corium

FDA to make decision on Corium’s transdermal patch for treating dementia next year

October 12, 2021 By Sean Whooley

Corium (NSDQ:CORI) announced today that the FDA set a Prescription Drug User Fee (PDUFA) target action date for its Adlarity system. The FDA set the PDUFA target action date for Adlarity (donepezil transdermal system), a transdermal patch designed to treat dementia or Alzheimer’s disease, for March 11, 2022. Get the full story at our sister site, […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Neurological, Pharmaceutical, Regulatory/Compliance Tagged With: Corium, FDA

FDA clears once-daily ADHD capsule from Corium

March 3, 2021 By Sean Whooley

Corium (NSDQ:CORI) announced today that it received FDA approval for its once-daily Azstarys oral capsule for treating ADHD symptoms. Boston-based Corium touts its Azstarys (serdexmethylphenidate [SDX] and dexmethylphenidate [d-MPH]) drug as the first and only product containing a d-MPH oral prodrug for treating ADHD (attention deficit hyperactivity disorder) symptoms in patients aged six years and older, […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Neurological, Pediatrics, Pharmaceutical, Regulatory/Compliance Tagged With: ADHD, Corium

DaVita taps Javier Rodriguez as CEO | Personnel Moves – April 29, 2019

April 29, 2019 By Fink Densford

DaVita Healthcare (NYSE:DVA) said today that its board of directors unanimously elected Javier Rodriguez to succeed Kent Thiry as its new CEO, effective June 1. The Denver-based company said that former CEO Thiry will transition to serve as executive chairman of the board, and that the announcement comes as part of a multi-year succession planning process. […]

Filed Under: Business/Financial News, Featured Tagged With: Avanos Medical (formerly Halyard Health), Baxter, biorad, Clinical Innovations, Corium, DaVita Inc., EarlySense, Electromed, Lantheus, meyerburger, micronsolutions, Shire Plc., The Pew Charitable Trusts

Corium touts clinical data for transdermal delivery of Alzheimer’s drug

July 18, 2017 By Sarah Faulkner

Corium (NSDQ:CORI) touted data today from a pilot bioequivalence study, comparing its Corplex Donepezil transdermal patch to oral Aricept as delivery method for the most commonly prescribed treatment for Alzheimer’s disease. Data from the pilot study demonstrated that Corium’s transdermal patch met the criteria for bioequivalence to oral Aricept, as measured by primary pharmacokinetic endpoints previously […]

Filed Under: Clinical Trials, Drug-Device Combinations, Food & Drug Administration (FDA), Neurological, Pharmaceutical, Wall Street Beat Tagged With: Corium

Medicare maintains reimbursement rate for Abiomed heart pump | Medtech Wall Street news for the week of Mar. 24, 2014

March 27, 2014 By MassDevice staff Leave a Comment

Abiomed jumps on Medicare reimbursement news

March 21, 2014 by Brad Perriello

Abiomed jumps on Medicare reimbursement news

Filed Under: News Well, Wall Street Beat Tagged With: Abiomed, Centers for Medicare and Medicaid Services (CMS), Corium, Haemonetics, Intuitive Surgical, Presbia, Red Cross

Corium poised for $66M IPO for wearable drug-delivery devices

March 24, 2014 By Arezu Sarvestani Leave a Comment

Corium poised for $66M IPO for wearable drug-delivery devices

Drug-delivery devices maker Corium could raise up to $66 million through an initial public offering, the company announced in SEC filings today.

Corium plans to offer 5.5 million shares of common stock for $10-$12 apiece, putting its total offering value at between $55-$66 million. At the middle rate of $11 per share, Corium expects its net proceeds to amount to $53.7 million after expenses.

Filed Under: Drug-Device Combinations, Initial Public Offering (IPO), News Well, Wall Street Beat Tagged With: Corium

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy